Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | CTSG | P08311 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21759695 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2HPGDLMNAPKMMME | |
| SCHEMBL8078351 | 0.91 | MME (0.58) | SMN1; SMN2MMEHDAC2HDAC8HDAC6 | |
| SCHEMBL7272374 | 0.91 | MME (0.58) | SMN1; SMN2MMEHDAC2HDAC8HDAC6 | |
| SCHEMBL26259892 | 0.89 | SMN1; SMN2 (0.60) | SMN1; SMN2HPGDLMNAPKMHDAC3 | |
| SCHEMBL20877889 | 0.89 | SMN1; SMN2 (0.60) | SMN1; SMN2HPGDLMNAPKMHDAC3 | |
| SCHEMBL22392193 | 0.88 | SMN1; SMN2 (0.59) | SMN1; SMN2HPGDLMNAPKMHDAC3 | |
| SCHEMBL9595087 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2HPGDLMNAPKMHDAC3 | |
| Leucine SCHEMBL10531667 | 0.84 | LTA4H (0.58) | MMELTA4HACE | |
| SCHEMBL10722448 | 0.84 | CTSG (0.68) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL6183685 | 0.83 | CTSL (0.63) | SMN1; SMN2HPGDLMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288559-A1 | PREP BINDING LIGANDS | POLKU THERAPEUTICS OY (FI) | 2025-09-18 | — | — | US | disclosed |
| CN-119451944-A | PREP binding ligands | 珀尔库治疗有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-12083108-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | CHDI FOUNDATION, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2023209191-A1 | PREP BINDING LIGANDS | UNIVERSITY OF HELSINKI (FI) | 2023-11-02 | — | — | WO | disclosed |
| US-20220409600-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11389438-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | CHDI FOUNDATION, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022042707-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021076723-A1 | ALKYLESTERS OF ALPHA-METHYL-DL-TYROSINE FOR USE IN TREATING CANCER | TYME, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20200276176-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | CHDI FOUNDATION, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-1888033-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | Biolipox AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| EP-1742622-A1 | USE OF LTB4 INHIBITORS FOR THE TREATMENT OF B-CELL LEUKEMIAS AND LYMPHOMAS | Biolipox AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006131737-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | BIOLIPOX AB (SE) | 2006-12-14 | — | — | WO | disclosed |
| WO-2005107725-A1 | USE OF LTB4 INHIBITORS FOR THE TREATMENT OF B-CELL LEUKEMIAS AND LYMPHOMAS | BIOLIPOX AB (SE) | 2005-11-17 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083108-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | HTT, HYPK, UBQLN2 | SMN1; SMN2 372/4885HPGD 3538/4885LMNA 3285/4885 |
| US-11389438-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | HTT, HYPK, UBQLN2 | SMN1; SMN2 372/4885HPGD 3538/4885LMNA 3285/4885 |
| US-20200276176-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | HTT, HYPK, UBQLN2 | SMN1; SMN2 372/4885HPGD 3538/4885LMNA 3285/4885 |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | SMN1; SMN2 4594/4885HPGD 285/4885LMNA 2837/4885 |
| US-20220409600-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | HTT, HYPK, UBQLN2 | SMN1; SMN2 372/4885HPGD 3538/4885LMNA 3285/4885 |
| US-20250288559-A1 | PREP BINDING LIGANDS | PREP, ERAP2, CTSA | SMN1; SMN2 3319/4885HPGD 3255/4885LMNA 1543/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | SMN1; SMN2 4594/4885HPGD 285/4885LMNA 2837/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | SMN1; SMN2 4699/4885HPGD 642/4885LMNA 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.